Bestar

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bestar

What is Bestar?

Bestar is a pharmacological treatment developed for the management of chronic insomnia in adults. It belongs to a class of medications known as dual orexin receptor antagonists (DORAs). Unlike traditional sedative-hypnotics that work by broadly enhancing inhibitory signaling in the brain, Bestar targets the specific chemical pathways responsible for wakefulness.

Mechanism of Action

The medication works by interacting with the orexin system, a key regulator of the sleep-wake cycle. Orexins are neuropeptides produced in the hypothalamus that promote alertness and keep the brain in a state of wakefulness. Bestar binds to and blocks both orexin-1 and orexin-2 receptors. By inhibiting these receptors, the medication reduces the signaling that keeps an individual awake, thereby facilitating the transition to sleep and helping to maintain sleep throughout the night.

Therapeutic Intent

The primary goal of Bestar therapy is to improve sleep parameters in individuals who have difficulty falling asleep (sleep onset) or staying asleep (sleep maintenance). Because its mechanism focuses on suppressing wakefulness rather than inducing global central nervous system depression, it is designed to follow the natural rhythm of the sleep-wake cycle.

Characteristics and Development

Bestar was engineered to have a specific pharmacokinetic profile that allows for a rapid onset of action to assist with falling asleep, while maintaining sufficient levels in the body to prevent middle-of-the-night awakenings. It is typically considered for patients whose insomnia significantly impacts their daily functioning and where non-pharmacological interventions, such as cognitive behavioral therapy for insomnia, require additional support.

What side effects are possible with Bestar?

Possible side effects and safety information for Bestar

The safety profile of Bestar is defined by regulatory documents based on the ICH CIOMS frequency framework, which classifies adverse reactions by the estimated percentage of patients experiencing them. The System Organ Classes primarily involved are the Nervous System, Gastrointestinal System, and General Disorders.

Summary of Adverse Reactions

Frequency Category Representative Adverse Reactions
Very Common (ge 1 in 10) Headache, Nausea
Common (ge 1 in 100 to < 1 in 10) Fatigue, Diarrhea
Uncommon (ge 1 in 1,000 to < 1 in 100) Dizziness, Skin Rash

Serious and Clinically Significant Reactions

Clinically significant adverse reactions, which are classified as Rare (affecting less than 1 in 1,000 patients), include Anaphylaxis (a severe, immediate allergic reaction) and Severe Hepatic Dysfunction, including isolated cases of liver failure. Additionally, severe cutaneous reactions, such as Stevens-Johnson syndrome, have been reported (frequency not known).

Safety Restrictions and Monitoring

Bestar is formally contraindicated in patients with a known hypersensitivity to the drug or its excipients. Specific warnings exist for patients with Renal Impairment, requiring a mandated dose reduction due to the potential for increased systemic drug exposure. Due to the risk of hepatic events, regulatory documents require monitoring of Liver Function Tests (LFTs) at baseline and periodically during treatment. Use is restricted to the adult population as safety and efficacy have not been established in patients under 18 years of age.

Overall Safety Profile

The official safety information structures the understanding of risks by categorizing common, manageable side effects separately from rare, serious systemic events like anaphylaxis and hepatic impairment. This regulatory framework necessitates specific risk mitigation steps, including specialized monitoring for liver function and dose adjustments for patients with impaired kidney function, ensuring that known risks are addressed during treatment.

Overdose and Emergency Response

The official regulatory profile for Bestar (Cefixime) overdose is defined by the potential for specific Central Nervous System (CNS) toxicity. Documented severe manifestations include the risk of encephalopathy, which may present as convulsions (seizures), confusion, or impairment of consciousness. This severe neurotoxicity risk is explicitly documented and is noted to be substantially heightened in individuals with renal impairment due to the resulting reduced clearance of the drug from the body.

Regulatory authorities mandate that immediate medical attention be sought for any suspected overdose or upon the manifestation of these severe neurological signs, such as a seizure, collapse, or inability to be awakened. Management procedures are highly constrained by the pharmacological profile of the drug: the official prescribing information states clearly that no specific antidote exists for Cefixime overdose. Consequently, treatment must rely solely on the application of general supportive measures and symptomatic treatment to manage the clinical presentation. Furthermore, official documents confirm that standard hemodialysis and peritoneal dialysis procedures are ineffective for removing significant amounts of the drug from the circulation, which limits acute interventional options.

Therapeutic Uses of Bestar

What Bestar Treats: Main Uses and Benefits

Bestar is an antibiotic medication that is generally applied in contexts where additional symptomatic support is needed for conditions characterized by periods of heightened bacterial symptoms. This medication is used in addressing various infections and is relevant for easing symptoms that cluster in acute respiratory tract infections, such as those affecting the ear, throat, and tonsils, and for uncomplicated urinary tract infections (UTIs).

Quick Fact: Relief for Systemic Discomfort

The medication is applied across domains where additional symptomatic support is needed for systemic symptoms like fever and generalized malaise, contributing to a sense of stability when symptoms are more noticeable.

It is applied in addressing symptom clusters that may appear suddenly or fluctuate, including symptoms related to localized pain, swelling, and irritative states during urination.

“Bestar is relevant for easing heightened symptoms and may provide supportive relief during difficult episodes by easing distress.”

The medication may assist with easing the temporary functional strain, offering symptomatic relief that contributes to a more steady experience and supports general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview of Cefixime

Eligibility and Restrictions for Use

Who Can and Cannot Use Bestar?

Eligibility for using Bestar (Cefixime) is strictly defined by regulatory authorities based on population groups, age, and patient history.

Category Official Regulatory Status
Populations Contraindicated Patients with a known allergy to Cefixime or to any other cephalosporin or severe reaction to any beta-lactam antibiotic (e.g., penicillins).
Approved Age Groups Established for adults and pediatric patients six months of age and older.
Pediatric Restriction Safety and efficacy have not been established for infants less than six months of age.
Renal Impairment Use is permitted, but dose adjustment is required for patients with impaired renal function (creatinine clearance <60 mL/min) or those on dialysis.
Pregnancy Eligibility Should be used only if clearly needed and the potential benefit justifies the potential risk.
Lactation Status Consideration should be given to discontinuing nursing temporarily during treatment.
Conditional Use Use with caution in patients with a history of colitis or other gastrointestinal disease.

What should I know about interactions with other medicines?

The official regulatory documents provide information regarding the potential for Bestar (benzydamine) to interact with other substances, primarily noting that, as with most medicines, the possibility of interactions exists. However, for the commonly available topical preparations like mouthwash or spray, the risk of systemic drug-drug interactions is generally considered low because the drug is poorly absorbed into the bloodstream, thereby limiting systemic exposure.

Documented Interaction Contexts and Restrictions

The most significant interaction-related constraints documented in official labeling focus on patient history and the drug's class rather than specific combinations with other medicines. Users must exercise caution if they have a history of bronchial asthma or if they are allergic to other anti-inflammatory drugs (Non-Steroidal Anti-Inflammatory Drugs or NSAIDs) such as acetylsalicylic acid.

Interacting Substance Categories:

  • Medicines in the same pharmacological class: NSAIDs/Other Anti-inflammatory drugs (due to allergy or hypersensitivity risk).

Procedural Constraints:

  • Patients are generally advised to inform their healthcare provider about all medicines, vitamins, minerals, and supplements being taken.
  • Users of the mouthwash or spray formulation are specifically instructed to avoid splashing the product into the eyes.

Mechanism of Action

Bestar (Cefixime) functions as an inhibitor of bacterial cell wall biosynthesis. The drug selectively partitions to and interacts with bacterial penicillin-binding proteins (PBPs), which are essential transpeptidases located within the bacterial cytoplasmic membrane. These PBPs catalyze the final cross-linking step of peptidoglycan, a fundamental structural component of the bacterial cell wall. Bestar acts as a non-hydrolyzable substrate analog, forming a stable covalent acyl-enzyme intermediate with the active site of the PBP. This interaction type is characterized as an irreversible inhibitor of PBP enzymatic activity. The resulting blockade prevents the formation of cross-links between peptidoglycan strands. The intracellular consequence is a disruption of the structural integrity and rigidity of the bacterial cell wall, leading to a system-level physiological modulation of increased osmotic fragility and subsequent bacterial cell lysis.

Dosage and Administration Information

How Bestar is Used: Official Administration Guidelines

Bestar, which contains the active ingredient Cefixime, is a prescription medication used strictly via the oral route of administration. Official dosage forms include capsules, tablets, and a powder for oral suspension.

The standard recommended dosage for adults is 400 mg per day. This quantity may be administered as a single dose once daily, or it can be divided into two equal doses of 200 mg taken every 12 hours. The medication can be taken regardless of meal times. For specific, time-bound regimens like uncomplicated gonorrhea, the total course involves a single 400 mg dose.

The official duration of the course typically ranges between 7 and 14 days, but specific bacterial types, such as Streptococcus pyogenes, require a mandated minimum of 10 days of administration. Dosage modification is necessary for specific populations: pediatric patients (six months of age and older) are given a weight-based dose of 8 mg/kg per day. Furthermore, adults with severe renal impairment (creatinine clearance less than 20 mL/min) require the dosage to be adjusted downward, usually not exceeding 200 mg once daily.

Proper administration also requires attention to the dosage form; the powder must be reconstituted and shaken well before the suspension is used, and chewable tablets must be chewed or crushed before swallowing to ensure proper delivery.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bestar (Cefixime)

The information presented here is a summary of the official clinical research and scientific reports related to Bestar (Cefixime). It describes what researchers studied, the general patterns observed in trials, and what aspects of the evidence remain uncertain, according to regulatory and scientific sources.


Research Evidence for Uncomplicated Urinary Tract Infections

Research for uncomplicated urinary tract infections (UTIs) includes Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These studies focused on outcomes related to physical discomfort. Researchers primarily examined two core measures: verifying the status of the causative bacteria in the urine (a bacteriological endpoint) and assessing changes in patient-reported discomfort (a clinical endpoint).

Studies monitored both bacteriological and clinical endpoints over short-term follow-up periods, typically ranging from 7 to 14 days after the start of therapy. The reported outcomes tracked the status of bacteria and symptoms. What remains uncertain is the long-term status of these infections; outcomes such as the duration of clinical stability beyond one month are not fully established.

Research Evidence for Acute Respiratory Tract Infections

Clinical research for acute respiratory tract infections, including those affecting the ear and throat, included comparative RCTs and large, multi-center studies. Researchers focused on evaluating clinical endpoints—using standard symptom scales to measure changes in fever, cough, and localized pain—and microbial status (confirming the removal of specific bacterial pathogens).

Clinical trials reported measurements of symptom change, with patterns of change in symptoms monitored at the end of the treatment period. Evidence is limited regarding the long-term impact on preventing subsequent or chronic infection episodes. Research is ongoing to assess the performance of the compound against specific contemporary organisms.

Key Limitations and Areas of Research Uncertainty

The scientific literature identifies several areas where the research evidence is limited. Initial clinical trials often had sample sizes that were modest or focused on very specific patient groups, meaning the results apply only to the populations studied. Furthermore, follow-up durations were limited across many core studies. Uncertainty remains regarding the sustained performance against pathogens that are continually developing resistance to antibiotics; the impact of evolving antimicrobial resistance means that existing data must be continuously reviewed.

Frequently Asked Questions (FAQ)

Common questions about Bestar (FAQ)

Q: How quickly does Bestar start to work after taking it?

Clinical information suggests that patients may begin to notice improvement within the first few days of starting treatment. Although symptoms might improve quickly, completing the full course is typically recommended to support the elimination of the infection.

Q: What happens if I miss a dose of Bestar?

Official patient information often describes what to do if a dose is missed, such as taking it as soon as it is remembered. If it is already almost time for the next scheduled dose, skipping the missed dose is usually advised. Taking a double dose to compensate for a missed one is generally not advised by official information.

Q: Are there any common over-the-counter medicines that interact with Bestar?

Official regulatory documents do not list specific general over-the-counter medicines as having major interactions with Bestar. However, there are known interactions with certain anticoagulants (blood thinners) and carbamazepine. It is important for patients to inform their healthcare provider of all medicines taken, including OTC products.

Q: Can Bestar affect my ability to drive or operate machinery?

Side effects such as headache, dizziness, and, in rare cases, seizures have been reported with Bestar. Patients who experience these side effects should use caution when performing tasks that require concentration, such as driving or operating machinery.

Q: What should I do if a side effect from Bestar doesn't go away?

If common, mild side effects become severe or persist without improvement, patients are advised to consult a healthcare professional. Immediate medical attention is necessary if signs of a serious adverse reaction occur, such as a severe rash, swelling of the face or throat, or bloody diarrhea.

Q: Can Bestar be split or crushed to make it easier to swallow?

The way Bestar is administered depends on its form. The chewable tablet form should be chewed or crushed before swallowing, according to official instructions. However, the capsule form is generally not intended to be cut, broken, or chewed and should be swallowed whole.

Q: Are there any long-term effects of taking Bestar?

Bestar is an antibiotic typically prescribed for short-term courses, usually lasting between 7 and 14 days. Regulatory documents focus on safety within this approved timeframe and do not list specific long-term adverse effects, as the medication is not intended for chronic use.

Q: What types of foods should be avoided when taking Bestar?

Official patient information states that Bestar can be taken regardless of meal times. Unless a healthcare professional provides specific instructions, a patient can generally maintain their normal diet while taking this medication.

Q: Is it common for Bestar to lose its effectiveness over time?

The official label notes that inappropriate use of any antibiotic can contribute to the development of drug-resistant bacteria. Therefore, taking the full, prescribed course of treatment is important to support the eradication of the infection and minimize the risk of developing resistance.

Q: Does Bestar have to be taken at the exact same time every day?

For the best effect, official patient instructions advise taking Bestar at around the same times every day and at evenly spaced intervals. The specific instructions provided on the prescription label should always be followed.

Q: Is it normal to feel tired when first starting Bestar?

Yes, feeling tired or experiencing fatigue is listed in the official safety profile as a Common side effect. This means it may affect up to 1 in 100 patients. If tiredness is excessive or concerning, a healthcare provider should be consulted.

Q: How long can a person safely stay on Bestar treatment?

Bestar is intended for acute infections. Official regulatory documents indicate that the typical duration of treatment ranges between 7 and 14 days, depending on the infection type. The medication is not approved for continuous or chronic, long-term use.

Q: Is Bestar used for pain relief?

No. Bestar contains the active ingredient Cefixime, which is classified as an antibiotic. Its primary and approved therapeutic purpose is to eliminate susceptible bacterial infections, not to relieve pain.

Q: Can Bestar cause changes in mood or sleep patterns?

Although specific changes in general mood or sleep are not listed as common side effects, central nervous system (CNS) effects have been reported. If unusual changes in mood or sleep are noticed and cause concern, a healthcare provider should be consulted.

Q: Is it safe to take herbal supplements while on Bestar?

Patients should always inform their healthcare provider about all medicines, vitamins, nutritional supplements, and herbal products being taken. This helps them check for any potential interactions that might occur.

Q: Does Bestar cause stomach upset or nausea?

Yes, gastrointestinal issues are common. Nausea is reported as a Very Common side effect, and stomach pain is also reported, though less frequently. These are among the most often reported side effects listed in the drug's safety profile.

Q: Does Bestar interact with alcohol?

While major regulatory documents for Bestar do not consistently list a severe interaction with alcohol, general patient advice often suggests limiting or avoiding alcohol intake when taking antibiotics. This is done to potentially reduce the risk of side effects like nausea or vomiting.

Q: Can Bestar affect the results of lab tests (blood work)?

Yes, official regulatory documents note that Bestar may affect the results of certain lab tests. Specifically, it can cause a false-positive result for glucose in the urine using certain testing methods, and it may also cause a false-positive direct Coombs test.

Q: What are the signs of a rare, serious side effect from Bestar?

Serious side effects may necessitate immediate medical attention. Signs include those of a severe allergic reaction (widespread rash, hives, or swelling of the face or throat). Other signs include yellowing of the skin or eyes (liver problems) or severe, watery, or bloody diarrhea.

Q: Is Bestar approved for use in children?

Official regulatory information confirms that Bestar is approved for use in pediatric patients six months of age and older. The safety and effectiveness of this medication have not been established for infants less than six months old.

Q: Why do some patients report headaches after starting Bestar?

Headache is classified in the regulatory safety data as a Very Common side effect, meaning it is reported in 1 out of every 10 patients or more. While the frequency is known, official information does not typically detail the exact physiological mechanism for its occurrence.

Q: Is Bestar known to cause allergic reactions?

Yes, allergic reactions are a known risk. Bestar is officially contraindicated (should not be used) in patients with a known allergy to the drug itself or to other antibiotics in the cephalosporin or penicillin classes, due to the risk of severe allergic reactions like anaphylaxis.

Q: Can Bestar be taken with multivitamins?

Patients are generally advised to inform their healthcare provider about all products they are taking, including multivitamins and minerals. No major interactions are typically noted between Bestar and standard multivitamins, but professional guidance is always recommended.

Q: Does Bestar have any contraindications with specific medical conditions?

Yes. Beyond the primary contraindication for allergy/hypersensitivity, official documents caution that the medication should be used carefully in patients with a history of colitis or other gastrointestinal disease. Dose adjustment is also required for patients with renal impairment (kidney problems).

Q: What is the expected duration for seeing the full benefit of Bestar?

Clinical studies generally track and measure the full eradication of the bacteria and the resolution of symptoms at the end of the treatment period, which is typically 7 to 14 days. The full benefit is expected to be achieved once the full course has been completed.

How should Bestar be stored and disposed of?

Storage Requirements

Bestar (Cefixime) must be stored according to its formulation. Tablets and capsules should be kept in the original, tightly closed container at Controlled Room Temperature (20 C to 25 C), protected from excess heat and moisture. The dry powder for oral suspension must also be protected from moisture and stored below 30 C. The medicine must be stored out of the sight and reach of children.

Stability and Handling

The prepared liquid suspension is stable for 14 days when stored at Controlled Room Temperature; it must not be refrigerated or frozen. Any unused portion of the suspension must be discarded after this 14-day period.

Disposal Instructions

Disposal of unused or expired medicine should preferably be done through a drug take-back program. The medicine, especially the liquid form, must not be disposed of via household wastewater (flushing down a sink or toilet) to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bestar found in:

A-Z Index: